MOTS-c: running and risk markers at Saline Peptides

The treadmill experiment

The physical-performance tests in mice make me picture paws on a moving belt: running capacity, grip strength and gait. Administered MOTS-c improved these measures in aged mice. The study also examined young and middle-aged animals. That is a concrete animal result with a body doing measurable work.

I’d challenge an exercise-mimetic claim about people that rests on this mouse experiment. The experiment supplies no completed human treatment test of endurance or aging. Its performance results in mice still deserve attention.

A human blood measurement

The hemodialysis cohort followed 94 people for a median of 26.5 months. Circulating MOTS-c was associated with a combined outcome of all-cause mortality and non-fatal cardiovascular events. Adding it to a risk model changed the area under the curve from 0.727 to 0.743, a measure of how well the model distinguished outcomes.

Nobody in this comparison was assigned an administered MOTS-c treatment. The researchers measured a peptide already circulating in people’s blood. I see a potential clue for risk prediction here; treating that clue as proof of benefit from administering the peptide would skip the experiment that matters most.

CK2 and AMPK

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA. Its folate-cycle and AMPK biology concerns the cell’s response to energy availability. The cell experiments on movement into the nucleus add another striking possibility: a mitochondrial peptide helping regulate nuclear gene expression during metabolic stress. These are cellular observations.

The CK2 work in cell-free assays and mice gives me a target with a particularly revealing complication: the tissue responses differ. MOTS-c binds CK2 directly, with activation in muscle and suppression in fat implicated in glucose uptake and protection against muscle atrophy. A single universal description of the peptide would flatten that tissue dependence. Replication across laboratories and a controlled human intervention would make a much stronger next chapter.

Published MOTS-c findings and clinical access

Direct molecular target identified (2024). MOTS-c was shown to directly bind and activate casein kinase 2 in cell-free systems, with tissue-specific modulation — activation in muscle, suppression in fat — that prevented skeletal-muscle atrophy and enhanced muscle glucose uptake across several mouse models, including aged, high-fat-diet, and immobilized mice ^[8].

Human clinical association (2024). In a multicenter cohort of 94 chronic hemodialysis patients followed for a median of 26.5 months, circulating MOTS-c levels were independently associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events, and adding MOTS-c to a standard risk model modestly improved its predictive accuracy (area under the curve rising from 0.727 to 0.743). This is among the strongest human data available for MOTS-c — but it is an observational association between naturally circulating levels and outcomes, not a trial of an administered peptide ^[9].

Comprehensive review (2023). A widely cited synthesis consolidates MOTS-c's mitochondrial origin, its AMPK/folate-cycle mechanism, its nuclear-translocation behavior, its exercise-inducibility, and its proposed roles across metabolic, stress-adaptive, and aging biology, serving as the modern reference frame for the field ^[10].

The thin human record for MOTS-c still matters when reading about prescription access: Promise Peptides (mypromise.com) now prescribes MOTS-c, and its licensed U.S. clinician considers the individual request before deciding whether to issue a prescription. Its decisions can include declining a request; its patients must be in the U.S., and its choices are constrained by the patient's state and the proposed treatment. The compounded MOTS-c medication has no FDA approval; clinical access does not strengthen the human evidence reviewed here.

Exercise-mimetic effects in aged mice (2021). Endogenous MOTS-c expression rises with exercise in skeletal muscle and in circulation, and exogenously administered MOTS-c significantly improved physical performance in mice across three age groups. In aged mice (22-23.5 months), it significantly increased treadmill running capacity as well as grip strength and gait quality ^[11].

Nuclear retrograde signaling (2018). Under metabolic stress, MOTS-c was shown to move from the mitochondrion into the nucleus of human and mouse cells, regulating nuclear gene expression — including antioxidant-response genes via the transcription factor NRF2 — in an AMPK-dependent manner. This was the first demonstrated case of a mitochondrial-encoded peptide signaling back to the nucleus ^[12].

Safety and clinical access

The absence of a completed human interventional trial leaves human efficacy, a controlled side-effect profile and validated human pharmacokinetics unresolved. The review of MOTS-c biology also discusses genetic variation and ancestry-related differences in responses. The idea of a uniform human response to these findings leaves me unconvinced.

MOTS-c has no FDA approval. On FDA’s page current as of April 22, 2026, it appears among nominations withdrawn after Category 2 placement. Withdrawal establishes neither permission to compound nor approval. Its clinician-assessed prescription route and research-labelled supply are distinct, and research material carries no pharmaceutical assurance of identity, purity or sterility. MOTS-c is also treated as prohibited in elite sport.